Stock Events

Stock Events

Karyopharm Therapeutics 

$0.018200
71
+$0.00+0%Wednesday 14:30

Statistics

Day High
0.0299
Day Low
0.017
52W High
10.99
52W Low
0.008
Volume
136,647,057
Avg. Volume
8,646,348
Mkt Cap
412,776.02
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Feb 10Expected
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
Next
-5.71
-3.91
-2.11
-0.31
Expected EPS
-0.31
Actual EPS
N/A

Financials

-134.21%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
146.07MRevenue
-196.04MNet Income

Analyst Ratings

$5.00Average Price Target
The highest estimate is ⁦7.00⁩.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
67%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KPTI. It's not an investment recommendation.
Apple
14
AAPL
Microsoft
14
MSFT
Amazon
14
AMZN
Alphabet
13
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap127.02B
Bristol Myers Squibb competes in the oncology space with a broad portfolio of cancer treatments, overlapping with Karyopharm's focus on cancer therapeutics.
Gilead Sciences
GILD
Mkt Cap207B
Gilead Sciences has a strong presence in the oncology and hematology market, directly competing with Karyopharm's cancer drug offerings.
AMGEN
AMGN
Mkt Cap249.05B
Amgen has a diverse range of cancer drugs that compete with Karyopharm's therapies in multiple myeloma and other cancers.
Merck
MRK
Mkt Cap361.73B
Merck & Co. is a leading pharmaceutical company with a strong lineup of cancer drugs that compete with Karyopharm's products.
Pfizer
PFE
Mkt Cap167.52B
Pfizer has a broad oncology portfolio, including treatments for conditions that Karyopharm's drugs target.
Abbvie
ABBV
Mkt Cap514.92B
AbbVie competes in the oncology market with a focus on cancer treatments, including therapies that could be in direct competition with Karyopharm's products.
Astrazeneca
AZN
Mkt Cap289.14B
AstraZeneca has a significant presence in the oncology sector, with drugs that compete against Karyopharm's offerings in cancer treatment.
Novartis
NVS
Mkt Cap307B
Novartis offers a wide range of cancer treatments, including therapies that directly compete with Karyopharm's products.
Johnson & Johnson
JNJ
Mkt Cap664.95B
Johnson & Johnson, through its pharmaceutical division Janssen, has a portfolio of cancer drugs that compete with Karyopharm's therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap93.55B
Regeneron Pharmaceuticals, though more focused on biotechnology, has been expanding its oncology portfolio, potentially competing with Karyopharm's cancer treatments.

About

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Show More
CEO
Richard A. Paulson
Employees
228
Country
United States
ISIN
US48576U2050
WKN
000A40YLC

Listings

STU
DE
25K0.STU
MU
DE
25K0.MU
BOATS
BOATS
KPTI.BOATS
NASDAQ
US
KPTI

0 Comments

Share your thoughts

FAQs

What is Karyopharm Therapeutics stock price today?▼
The current price of KPTI is $0.02 USD — it has increased by +0% in the past 24 hours. Watch Karyopharm Therapeutics stock price performance more closely on the chart.
What is Karyopharm Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Karyopharm Therapeutics stocks are traded under the ticker KPTI.
What is Karyopharm Therapeutics market cap?▼
Today Karyopharm Therapeutics has the market capitalization of 412,776.02
When is the next Karyopharm Therapeutics earnings date?▼
Karyopharm Therapeutics is going to release the next earnings report on February 10, 2027.
What is Karyopharm Therapeutics revenue for the last year?▼
Karyopharm Therapeutics revenue for the last year amounts to 146.07M USD.
What is Karyopharm Therapeutics net income for the last year?▼
KPTI net income for the last year is -196.04M USD.
How many employees does Karyopharm Therapeutics have?▼
As of November 14, 2026, the company has 228 employees.
In which sector is Karyopharm Therapeutics located?▼
Karyopharm Therapeutics operates in the Health & Wellness sector.
When did Karyopharm Therapeutics complete a stock split?▼
The last stock split for Karyopharm Therapeutics was on February 26, 2025 with a ratio of 1:15.
Where is Karyopharm Therapeutics headquartered?▼
Karyopharm Therapeutics is headquartered in NEWTON, United States.